Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (7821)	10/12/2001 11:48:21 AM
From: tyc:>	Read Replies (1) \| Respond to of 14101

Let's see if T.A. provides better investment results than prudence or fundamental analysis. Message 16493818 Technically, IMHO the chart looks good today !

To: Montana Wildhack who wrote (7821)	10/15/2001 5:06:16 AM
From: twentyfirstcenturyfox	Read Replies (1) \| Respond to of 14101

<Management milestones have been slow versus average timelines; but, have now resulted in the first billion of servicable market. As a result near term risk is focused on interim cash management until those markets mature>. Wolf, this is the essence of the short term quandry which has lead to the weakness in the shareprice, and the financing difficulties (or excessive dilution) that are implicit therein. May I summarize what i find vital in recent posts (esp yours) questions to raise at the AGM? 1. MANAGEMENT: history - Inexperienced management, lack of major bio on board, evidenced by delays in the drug approval process in North America and in not anticipating problems in the EU reciprocal process. Future: what can DMX say to assure us shareholders that it plans to take on additional expertise to ensure a speedy resolution of the multiple needs of the EU approval process? 2. INVESTOR RELATIONS: the performance of the stock price speaks volumes. Likewise the incomplete News Release about the EU. Since DMX is wholly reliant on its stock price to generate capital and minimize the dilution of equity, what changes does management propose to improve the profile of the company and attract institutional support? 3. CASH FLOWS: are the life's blood of this company. They are uncertain, at this time. Please identify how the company will source the finance for its plans, over the remainder of this fiscal year. Specifically, what is the projected cash burn rate for - obtaining EU approval; - completing ramp up for the North American markets; - completion of the OXO buy-out; - completion of the WF-10 drug approval application (to FDA) process; - all ongoing operations and capital asset needs. 4. ACQUA WELLINGTON: this agreement, for 8% discounted shares extends until January, 2002 with approximately 44 million remaining. Does DMX have the ability, at its sole discretion, to extend this financing agreement? In other words, is this an secure source, ongoing past Jan 2002? 5. OXO ACQUISITION: since DMX has a stock price that is relatively weak, and since it is likely that this will be an all stock and debt for stock transaction, has DMX contemplated deferring completion of the transaction, until the stock market better reflects DMX's value? Fox.